Who Paid My Doc
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
ClinicalTrials.gov NCT03271489
Research payments
$1,369,236
Through program year 2022, $1,369,236 in research payments was reported against Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women, across 632 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT03271489
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $1,369,236 | 632 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Liesl Bredeson Dallas, TX Named on 48 payments
- Pamela Moore Plano, TX Named on 22 payments
- Ramin Farsad Encinitas, CA Named on 22 payments
- Alyssa Kratochvil Fall River, MA Named on 18 payments
- Kwabena Ayesu Orlando, FL Named on 15 payments
- Nora Doty Portland, OR Named on 15 payments
- Bryan Feldman Columbus, OH Named on 15 payments
- Delbert Johns Fort Worth, TX Named on 14 payments
- Awoniyi Awonuga Southfield, MI Named on 14 payments
- Parke Hedges San Antonio, TX Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.